Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 2.68B | 2.48B | 2.09B | 1.78B | 1.41B |
Gross Profit | 1.69B | 1.58B | 1.34B | 1.11B | 924.21M |
EBITDA | 695.19M | 534.00M | 383.89M | 309.47M | 119.66M |
Net Income | 385.80M | 310.98M | 198.03M | 133.73M | 62.37M |
Balance Sheet | |||||
Total Assets | 7.50B | 6.54B | 5.81B | 5.22B | 3.96B |
Cash, Cash Equivalents and Short-Term Investments | 3.20B | 2.85B | 3.32B | 3.51B | 2.74B |
Total Debt | 518.96M | 8.78M | 5.89M | 0.00 | 0.00 |
Total Liabilities | 4.87B | 3.85B | 3.51B | 3.11B | 2.64B |
Stockholders Equity | 2.63B | 2.69B | 2.30B | 2.10B | 1.32B |
Cash Flow | |||||
Free Cash Flow | -10.11M | 132.97M | 39.77M | 264.81M | -164.34M |
Operating Cash Flow | 467.69M | 334.63M | 99.67M | 469.29M | 239.00M |
Investing Cash Flow | -259.08M | -811.77M | -285.10M | 404.17M | -520.26M |
Financing Cash Flow | 146.70M | -1.33M | -869.00K | 644.37M | 0.00 |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | ¥13.87B | 284.55 | 0.72% | -13.57% | -106.11% | ||
67 Neutral | ¥10.53B | 27.29 | ― | 7.98% | 24.12% | ||
58 Neutral | ¥25.02B | ― | ― | -2.34% | -278.32% | ||
52 Neutral | $7.59B | 0.18 | -63.14% | 2.16% | 16.34% | 0.64% | |
49 Neutral | ¥21.32B | 215.00 | ― | 8.46% | 49.97% | ||
47 Neutral | ¥19.20B | ― | ― | -100.00% | -1079.89% | ||
46 Neutral | ¥16.40B | ― | ― | -4.04% | -0.88% |
StemCell Institute Inc. has entered a joint venture with BIG RAINBOW INVESTMENT PTE. LTD., the family office of Sinar Mas Group, to expand its cell banking business in Southeast Asia. This strategic partnership aims to leverage StemCell’s expertise and the local networks of Sinar Mas Group to strengthen its presence and achieve sustainable growth in the region, with plans to explore related regenerative medicine services.